Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;36(3):152-159.
doi: 10.1002/kjm2.12161. Epub 2019 Dec 9.

Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Ming-Yii Huang  1   2   3   4   5 , Ching-Wen Huang  6   7 , Jaw-Yuan Wang  3   4   5   6   7   8   9
Affiliations
Review

Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Ming-Yii Huang et al. Kaohsiung J Med Sci. 2020 Mar.

Abstract

Colorectal cancer is a major public health problem worldwide, and locally advanced rectal cancer (LARC) is known for its poor prognosis. A multimodal treatment approach is the only method to achieve satisfactory local recurrence and survival rates in LARC. Determining which therapeutic modality for LARC has the most satisfactory influence on quality of life and disease outcome is still controversial. LARC treatment is subject to continuous advancement due to the development of new and better diagnostic tools, radiotherapy techniques, and chemotherapeutic agents. Herein, we review various therapeutic modalities for LARC from several aspects. In addition to radiotherapy techniques such as neoadjuvant chemoradiotherapy (NCRT), we discuss the progress of chemotherapy, appropriate time interval between NCRT and surgery, relationship between tumor location and NCRT efficacy/safety, wait-and-watch policy, and predictors of treatment response following NCRT. Because of the controversies and unanswered questions regarding NCRT treatments for LARC, additional investigations are required to determine which therapeutic approach is the most feasible for LARC patients.

Keywords: local recurrence; locally advanced rectal cancer; neoadjuvant chemoradiotherapy; surgery.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflicts of interest.

References

    1. Tepper JE, O'Connell M, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, et al. Adjuvant therapy in rectal cancer: Analysis of stage, sex, and local control – final report of intergroup 0114. J Clin Oncol. 2002;20(7):1744–1750. - PubMed
    1. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638–646. - PubMed
    1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740. - PubMed
    1. Minsky BD. Oxaliplatin‐based combined‐modality therapy for rectal cancer. Semin Oncol. 2003;30(4 Suppl 15):26–33. - PubMed
    1. Kim DW, Lim SB, Kim DY, Kim TH, Jung KH, Kim DH, et al. Pre‐operative chemo‐radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge. Eur J Surg Oncol. 2006;32(2):162–167. - PubMed

LinkOut - more resources